cmv-mva
Vaccineexperimental
Clinical trial activity
3 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
2
Phase 3
0
Phase 4
0
Earliest trial started Oct 31, 2018 (NCT03383055)
Timeline
Indications
Mechanism of action
- CytomegalovirusImmunity, active
Cytomegalovirus immunity, active
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06075745 | Phase 2 | Dec 1, 2023 | National Institute of Allergy and Infectious Diseases (NIAID) |
| NCT05099965 | Phase 2 | Nov 2, 2021 | AIDS Clinical Trials Group, National Institute of Allergy and Infectious Diseases (NIAID) |
| NCT03383055 | Phase 1 | Oct 31, 2018 | University of Minnesota |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| National Institute of Allergy and Infectious Diseases (NIAID) | Government | 2 | 2 | 1 | 2021 |
| AIDS Clinical Trials Group | Academic/Hospital | 1 | 0 | 1 | 2021 |
| University of Minnesota | Academic/Hospital | 1 | 1 | 1 | 2018 |
3 organizations
Page 1 / 1